CEC Oncology is pleased to offer your facility a complimentary, accredited Grand Rounds presentation entitled, B-Cell Malignancies Tumor Board: Therapeutic Decision-Making in Challenging Clinical Scenarios This presentation is available from February 28, 2019 through December 31, 2019.

Activity Overview
B-cell Non-Hodgkin lymphoma is a heterogeneous group of malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and hairy cell leukemia. This diverse spectrum of B-cell malignancies, together with the recent introduction of targeted therapies and immune-cell engineering, has resulted in an unprecedented choice of tolerable and effective therapeutic options for B-cell malignancies, including BTK inhibitors, BCL2 inhibitors, and monoclonal antibodies, among others. Given the rapidity of discovery, many clinicians who treat patients with these malignancies have yet to develop the body of knowledge and clinical judgment required to best incorporate these agents into their own practice. Thus, it is imperative that clinicians learn how to select, sequence, and combine new therapeutic approaches based on a complex set of patient, tumor, and treatment-history factors in an effort to optimize clinical outcomes and patient health.

This Grand Rounds series is based on a tumor board model in which faculty will present patient cases and lead discussions regarding proposed treatment approaches, including appropriate sequencing and combination regimens based on the latest trial data and patient- and tumor-specific factors. The presentation will also include strategies to successfully incorporate these novel therapies into clinical practice and address barriers to their use in B-cell malignancies, including patient adherence and management of drug-associated toxicities. This Grand Rounds series will draw attendees into the process of peer discussion and encourage the promotion of collaborative exchange with other members of the oncology care team to ensure optimal patient outcomes.